Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria
1
,
Zsuzsanna Márk
1
,
Petr Zatloukal
1
,
Barna Szima
1
,
Istvan Albert
1
,
Erzsébet Juhász
1
,
Jean Louis Pujol
1
,
Jerzy Kozielski
1
,
Nigel Baker
1
,
Dominic Smethurst
1
,
Yong-Jiang Hei
1
,
Avi Ashkenazi
1
,
Howard Stern
1
,
Lukas Amler
1
,
Yang Pan
1
,
Fiona Blackhall
1
Publication type: Journal Article
Publication date: 2011-11-20
scimago Q1
wos Q1
SJR: 11.205
CiteScore: 38.9
Impact factor: 41.9
ISSN: 0732183X, 15277755
PubMed ID:
22010015
Cancer Research
Oncology
Abstract
Purpose
To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non–small-cell lung cancer (NSCLC).
Patients and Methods
Patients with squamous NSCLC and/or CNS metastases received PC every 3 weeks alone (arm 1) or with dulanermin 8 mg/kg for 5 days (arm 2). Patients with nonsquamous NSCLC received PCB alone (arm 3) or with dulanermin 8 mg/kg for 5 days (arm 4) or 20 mg/kg for 2 days (arm 5). The primary end point was the objective response rate (ORR).
Results
Overall, 213 patients were randomly assigned (arm 1, n = 41; arm 2, n = 39; arm 3, n = 42; arm 4, n = 40; arm 5, n = 41). The ORR in arms 1 to 5 was 39% (95% CI, 24% to 56%), 38% (95% CI, 24% to 54%), 50% (95% CI, 35% to 65%), 40% (95% CI, 25% to 56%), and 40% (95% CI, 25% to 56%), respectively. The odds ratio for ORR was 1.04 (P = 1.000) for arm 1 versus arm 2, 1.53 (P = .391) for arm 3 and versus arm 4, and 1.53 (P = .391) for arm 3 versus arm 5. The most common grade ≥ 3 adverse events were neutropenia, asthenia, anemia, thrombocytopenia, and hemoptysis. Of 161 available serum samples, a trend toward increased caspase-cleaved cytokeratin-18 was observed after dulanermin treatment in cycles 1 and 2. Among 84 patients evaluated for GalNT14 expression, there was a trend toward favorable progression-free survival and overall survival with dulanermin treatment in those with high GalNT14 expression.
Conclusion
The addition of dulanermin to PC and PCB did not improve outcomes in unselected patients with previously untreated advanced or recurrent NSCLC.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
Cancers
8 publications, 3.85%
|
|
|
Oncotarget
7 publications, 3.37%
|
|
|
PLoS ONE
7 publications, 3.37%
|
|
|
Cell Death and Disease
6 publications, 2.88%
|
|
|
Oncogene
5 publications, 2.4%
|
|
|
Molecular Cancer Therapeutics
5 publications, 2.4%
|
|
|
Journal of Clinical Investigation
3 publications, 1.44%
|
|
|
International Journal of Oncology
3 publications, 1.44%
|
|
|
Oncology Reports
3 publications, 1.44%
|
|
|
Nature Reviews Drug Discovery
3 publications, 1.44%
|
|
|
Cancer Chemotherapy and Pharmacology
3 publications, 1.44%
|
|
|
Journal of Thoracic Oncology
3 publications, 1.44%
|
|
|
Journal of Controlled Release
3 publications, 1.44%
|
|
|
Journal of Investigative Dermatology
3 publications, 1.44%
|
|
|
Resistance to Targeted Anti-Cancer Therapeutics
3 publications, 1.44%
|
|
|
International Journal of Molecular Sciences
2 publications, 0.96%
|
|
|
Journal of Clinical Medicine
2 publications, 0.96%
|
|
|
Stem Cell Reviews and Reports
2 publications, 0.96%
|
|
|
Apoptosis : an international journal on programmed cell death
2 publications, 0.96%
|
|
|
Cell Death and Differentiation
2 publications, 0.96%
|
|
|
Cell Death Discovery
2 publications, 0.96%
|
|
|
Critical Reviews in Oncology/Hematology
2 publications, 0.96%
|
|
|
Biomedicine and Pharmacotherapy
2 publications, 0.96%
|
|
|
Biomaterials
2 publications, 0.96%
|
|
|
Advanced healthcare materials
2 publications, 0.96%
|
|
|
Molecular Carcinogenesis
2 publications, 0.96%
|
|
|
mAbs
2 publications, 0.96%
|
|
|
OncoImmunology
2 publications, 0.96%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 0.96%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Springer Nature
46 publications, 22.12%
|
|
|
Elsevier
46 publications, 22.12%
|
|
|
MDPI
17 publications, 8.17%
|
|
|
Wiley
14 publications, 6.73%
|
|
|
Taylor & Francis
12 publications, 5.77%
|
|
|
Spandidos Publications
8 publications, 3.85%
|
|
|
Impact Journals
7 publications, 3.37%
|
|
|
Public Library of Science (PLoS)
7 publications, 3.37%
|
|
|
American Association for Cancer Research (AACR)
7 publications, 3.37%
|
|
|
Frontiers Media S.A.
5 publications, 2.4%
|
|
|
SAGE
4 publications, 1.92%
|
|
|
American Society for Clinical Investigation
3 publications, 1.44%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 1.44%
|
|
|
American Chemical Society (ACS)
2 publications, 0.96%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.96%
|
|
|
eLife Sciences Publications
2 publications, 0.96%
|
|
|
OAE Publishing Inc.
2 publications, 0.96%
|
|
|
S. Karger AG
1 publication, 0.48%
|
|
|
Portland Press
1 publication, 0.48%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.48%
|
|
|
IOP Publishing
1 publication, 0.48%
|
|
|
Maad Rayan Publishing Company
1 publication, 0.48%
|
|
|
Neoplasia Press
1 publication, 0.48%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.48%
|
|
|
BMJ
1 publication, 0.48%
|
|
|
Hindawi Limited
1 publication, 0.48%
|
|
|
Springer New York
1 publication, 0.48%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.48%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.48%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
208
Total citations:
208
Citations from 2024:
19
(9.14%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Soria J. et al. Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer // Journal of Clinical Oncology. 2011. Vol. 29. No. 33. pp. 4442-4451.
GOST all authors (up to 50)
Copy
Soria J., Márk Z., Zatloukal P., Szima B., Albert I., Juhász E., Pujol J. L., Kozielski J., Baker N., Smethurst D., Hei Y., Ashkenazi A., Stern H., Amler L., Pan Y., Blackhall F. Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer // Journal of Clinical Oncology. 2011. Vol. 29. No. 33. pp. 4442-4451.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1200/jco.2011.37.2623
UR - https://doi.org/10.1200/jco.2011.37.2623
TI - Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
T2 - Journal of Clinical Oncology
AU - Soria, Jean-Charles
AU - Márk, Zsuzsanna
AU - Zatloukal, Petr
AU - Szima, Barna
AU - Albert, Istvan
AU - Juhász, Erzsébet
AU - Pujol, Jean Louis
AU - Kozielski, Jerzy
AU - Baker, Nigel
AU - Smethurst, Dominic
AU - Hei, Yong-Jiang
AU - Ashkenazi, Avi
AU - Stern, Howard
AU - Amler, Lukas
AU - Pan, Yang
AU - Blackhall, Fiona
PY - 2011
DA - 2011/11/20
PB - American Society of Clinical Oncology (ASCO)
SP - 4442-4451
IS - 33
VL - 29
PMID - 22010015
SN - 0732-183X
SN - 1527-7755
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2011_Soria,
author = {Jean-Charles Soria and Zsuzsanna Márk and Petr Zatloukal and Barna Szima and Istvan Albert and Erzsébet Juhász and Jean Louis Pujol and Jerzy Kozielski and Nigel Baker and Dominic Smethurst and Yong-Jiang Hei and Avi Ashkenazi and Howard Stern and Lukas Amler and Yang Pan and Fiona Blackhall},
title = {Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer},
journal = {Journal of Clinical Oncology},
year = {2011},
volume = {29},
publisher = {American Society of Clinical Oncology (ASCO)},
month = {nov},
url = {https://doi.org/10.1200/jco.2011.37.2623},
number = {33},
pages = {4442--4451},
doi = {10.1200/jco.2011.37.2623}
}
Cite this
MLA
Copy
Soria, Jean-Charles, et al. “Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer.” Journal of Clinical Oncology, vol. 29, no. 33, Nov. 2011, pp. 4442-4451. https://doi.org/10.1200/jco.2011.37.2623.